[Chinese expert consensus on prevention and treatment of immunotherapeutic and molecular targeted agents-related infections in patients with hematological malignancies (2025)].

Abstract

As novel therapeutic agents continue to emerge, immunotherapy and molecular-targeted drugs demonstrate expanding application prospects in hematological malignancy treatment. This expert consensus revision incorporates the latest evidence-based medicine from domestic and international sources, updating recommendations for infection diagnosis, prevention, and treatment. The document integrates recommendations for recently launched or imminent antibodies and small molecule targeted compounds, including COVID-19 considerations. This format of recommendations is modified according to the levels of evidence of The Oxford Centre for Evidence-Based Medicine (CEBM).